1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Medical Treatement
1.2.3 Liver Transplantation
1.2.4 Others
1.3 Market by Application
1.3.1 Global Primary Sclerosing Cholangitis (PSC) Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Sclerosing Cholangitis (PSC) Market Perspective (2018-2029)
2.2 Primary Sclerosing Cholangitis (PSC) Growth Trends by Region
2.2.1 Global Primary Sclerosing Cholangitis (PSC) Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Sclerosing Cholangitis (PSC) Historic Market Size by Region (2018-2023)
2.2.3 Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Region (2024-2029)
2.3 Primary Sclerosing Cholangitis (PSC) Market Dynamics
2.3.1 Primary Sclerosing Cholangitis (PSC) Industry Trends
2.3.2 Primary Sclerosing Cholangitis (PSC) Market Drivers
2.3.3 Primary Sclerosing Cholangitis (PSC) Market Challenges
2.3.4 Primary Sclerosing Cholangitis (PSC) Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue
3.1.1 Global Top Primary Sclerosing Cholangitis (PSC) Players by Revenue (2018-2023)
3.1.2 Global Primary Sclerosing Cholangitis (PSC) Revenue Market Share by Players (2018-2023)
3.2 Global Primary Sclerosing Cholangitis (PSC) Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Sclerosing Cholangitis (PSC) Revenue
3.4 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio
3.4.1 Global Primary Sclerosing Cholangitis (PSC) Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Sclerosing Cholangitis (PSC) Revenue in 2022
3.5 Primary Sclerosing Cholangitis (PSC) Key Players Head office and Area Served
3.6 Key Players Primary Sclerosing Cholangitis (PSC) Product Solution and Service
3.7 Date of Enter into Primary Sclerosing Cholangitis (PSC) Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Type
4.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Type (2018-2023)
4.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Type (2024-2029)
5 Primary Sclerosing Cholangitis (PSC) Breakdown Data by Application
5.1 Global Primary Sclerosing Cholangitis (PSC) Historic Market Size by Application (2018-2023)
5.2 Global Primary Sclerosing Cholangitis (PSC) Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
6.2 North America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
6.4 North America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
7.2 Europe Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
7.4 Europe Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
8.2 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2018-2023)
8.4 Asia-Pacific Primary Sclerosing Cholangitis (PSC) Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
9.2 Latin America Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
9.4 Latin America Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size (2018-2029)
10.2 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2018-2023)
10.4 Middle East & Africa Primary Sclerosing Cholangitis (PSC) Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Acorda Therapeutics
11.1.1 Acorda Therapeutics Company Detail
11.1.2 Acorda Therapeutics Business Overview
11.1.3 Acorda Therapeutics Primary Sclerosing Cholangitis (PSC) Introduction
11.1.4 Acorda Therapeutics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.1.5 Acorda Therapeutics Recent Development
11.2 Gilead Sciences
11.2.1 Gilead Sciences Company Detail
11.2.2 Gilead Sciences Business Overview
11.2.3 Gilead Sciences Primary Sclerosing Cholangitis (PSC) Introduction
11.2.4 Gilead Sciences Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.2.5 Gilead Sciences Recent Development
11.3 NGM Biopharmaceuticals
11.3.1 NGM Biopharmaceuticals Company Detail
11.3.2 NGM Biopharmaceuticals Business Overview
11.3.3 NGM Biopharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.3.4 NGM Biopharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.3.5 NGM Biopharmaceuticals Recent Development
11.4 Intercept Pharmaceuticals
11.4.1 Intercept Pharmaceuticals Company Detail
11.4.2 Intercept Pharmaceuticals Business Overview
11.4.3 Intercept Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.4.4 Intercept Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.4.5 Intercept Pharmaceuticals Recent Development
11.5 Dr. Falk Pharma
11.5.1 Dr. Falk Pharma Company Detail
11.5.2 Dr. Falk Pharma Business Overview
11.5.3 Dr. Falk Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.5.4 Dr. Falk Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.5.5 Dr. Falk Pharma Recent Development
11.6 Allergan
11.6.1 Allergan Company Detail
11.6.2 Allergan Business Overview
11.6.3 Allergan Primary Sclerosing Cholangitis (PSC) Introduction
11.6.4 Allergan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.6.5 Allergan Recent Development
11.7 Shire
11.7.1 Shire Company Detail
11.7.2 Shire Business Overview
11.7.3 Shire Primary Sclerosing Cholangitis (PSC) Introduction
11.7.4 Shire Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.7.5 Shire Recent Development
11.8 Durect Corporation
11.8.1 Durect Corporation Company Detail
11.8.2 Durect Corporation Business Overview
11.8.3 Durect Corporation Primary Sclerosing Cholangitis (PSC) Introduction
11.8.4 Durect Corporation Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.8.5 Durect Corporation Recent Development
11.9 Conatus Pharmaceuticals
11.9.1 Conatus Pharmaceuticals Company Detail
11.9.2 Conatus Pharmaceuticals Business Overview
11.9.3 Conatus Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.9.4 Conatus Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.9.5 Conatus Pharmaceuticals Recent Development
11.10 Sirnaomics
11.10.1 Sirnaomics Company Detail
11.10.2 Sirnaomics Business Overview
11.10.3 Sirnaomics Primary Sclerosing Cholangitis (PSC) Introduction
11.10.4 Sirnaomics Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.10.5 Sirnaomics Recent Development
11.11 Shenzhen HighTide Biopharmaceutical
11.11.1 Shenzhen HighTide Biopharmaceutical Company Detail
11.11.2 Shenzhen HighTide Biopharmaceutical Business Overview
11.11.3 Shenzhen HighTide Biopharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.11.4 Shenzhen HighTide Biopharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.11.5 Shenzhen HighTide Biopharmaceutical Recent Development
11.12 Glenmark
11.12.1 Glenmark Company Detail
11.12.2 Glenmark Business Overview
11.12.3 Glenmark Primary Sclerosing Cholangitis (PSC) Introduction
11.12.4 Glenmark Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.12.5 Glenmark Recent Development
11.13 Impax Laboratories
11.13.1 Impax Laboratories Company Detail
11.13.2 Impax Laboratories Business Overview
11.13.3 Impax Laboratories Primary Sclerosing Cholangitis (PSC) Introduction
11.13.4 Impax Laboratories Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.13.5 Impax Laboratories Recent Development
11.14 Mylan
11.14.1 Mylan Company Detail
11.14.2 Mylan Business Overview
11.14.3 Mylan Primary Sclerosing Cholangitis (PSC) Introduction
11.14.4 Mylan Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.14.5 Mylan Recent Development
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Detail
11.15.2 Teva Pharmaceuticals Business Overview
11.15.3 Teva Pharmaceuticals Primary Sclerosing Cholangitis (PSC) Introduction
11.15.4 Teva Pharmaceuticals Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.15.5 Teva Pharmaceuticals Recent Development
11.16 Daewoong Pharmaceutical
11.16.1 Daewoong Pharmaceutical Company Detail
11.16.2 Daewoong Pharmaceutical Business Overview
11.16.3 Daewoong Pharmaceutical Primary Sclerosing Cholangitis (PSC) Introduction
11.16.4 Daewoong Pharmaceutical Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.16.5 Daewoong Pharmaceutical Recent Development
11.17 Mitsubishi Tanabe Pharma
11.17.1 Mitsubishi Tanabe Pharma Company Detail
11.17.2 Mitsubishi Tanabe Pharma Business Overview
11.17.3 Mitsubishi Tanabe Pharma Primary Sclerosing Cholangitis (PSC) Introduction
11.17.4 Mitsubishi Tanabe Pharma Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.17.5 Mitsubishi Tanabe Pharma Recent Development
11.18 Lannett
11.18.1 Lannett Company Detail
11.18.2 Lannett Business Overview
11.18.3 Lannett Primary Sclerosing Cholangitis (PSC) Introduction
11.18.4 Lannett Revenue in Primary Sclerosing Cholangitis (PSC) Business (2018-2023)
11.18.5 Lannett Recent Development
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
※参考情報 原発性硬化性胆管炎(PSC)は、主に肝臓と胆管に影響を及ぼす慢性の肝疾患です。この病態は、胆管の炎症、硬化、および狭窄を伴い、最終的には胆汁の流れが妨げられ、胆管に異常が生じることが特徴です。PSCは、自己免疫的要因や遺伝的要因が影響する可能性があり、多くの場合、他の自己免疫疾患と関連して発症します。 PSCは、特に中年以降の男性に多く見られる疾患ですが、女性にも発症します。患者は、慢性的な胆管の炎症により、胆管の狭窄や閉塞を経験し、その結果として胆汁の流れが妨げられます。これにより、患者はしばしば黄疸、かゆみ、腹痛、体重減少などの症状を呈します。また、PSCは肝硬変や肝細胞癌のリスクを高めることが知られています。 原発性硬化性胆管炎は、臨床的には「一次性」と「二次性」の2つに大別できます。一次性硬化性胆管炎は、特定の明確な原因が特定されない進行性の疾患であり、自己免疫疾患や特定の遺伝的素因が疑われています。一方、二次性硬化性胆管炎は、胆管に対する外部の要因、例えば胆石症、腫瘍、感染などによって引き起こされることが多いです。 PSCが発症するメカニズムは未だ解明されていない部分が多いですが、遺伝的要因や免疫系の異常が大きな役割を果たしていると考えられています。一部の研究では、主に特定の遺伝子変異がPSCの発症に関連していることが示唆さています。また、PSCは通常、潰瘍性大腸炎やクローン病などの炎症性腸疾患と関連して見られることが多いです。この相関関係が何を意味するのかについては、さらなる研究が必要とされています。 PSCの診断は、通常、血液検査、画像診断、内視鏡的検査によって行われます。血液検査では、肝機能の異常や胆道系の酵素の上昇などが確認されます。画像診断においては、MRIやCT、超音波などを用い、胆管の状態を評価します。また、ERCP(内視鏡的逆行性胆管膵管造影)を用いた検査でも、胆管の形状や狭窄の程度を詳細に評価することができます。 治療に関しては、PSCに対する特異的な治療法は現在のところ存在しません。しかし、症状の軽減や合併症の予防を目的とした管理が重要です。肝機能の正常化や胆汁の流れを改善するために、薬物療法が用いられることがあります。また、症状が重篤な場合や肝硬変が進行している場合には、肝移植が唯一の治療法として考慮されることがあります。 関連技術としては、新しいバイオマーカーの発見や、遺伝子分析を用いたリスク評価の研究が進行中です。これにより、PSCの早期診断や治療戦略の向上が期待されています。さらに、免疫療法や生物学的製剤の開発も行われており、今後の治療の選択肢としての可能性が模索されています。 原発性硬化性胆管炎は、慢性な病態であり、一度発症すると長期間にわたって管理が求められます。患者さんは、定期的なフォローアップと医療チームとの継続的なコミュニケーションが重要です。また、疾患に関する正しい知識を持つことが、自身の健康管理につながります。 このように、原発性硬化性胆管炎は非常に複雑で多面的な疾患であり、日々の研究によって新たな知見が得られています。患者の生活の質を向上させるためにも、さらに多くの理解と対策が必要とされています。 |